Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DAD95G
|
|||
| Drug Name |
VX-371
|
|||
| Indication | Cystic fibrosis [ICD-11: CA25; ICD-10: E84, E84.9] | Phase 2 | [1] | |
| Primary ciliary dyskinesia [ICD-11: LA75.Y; ICD-9: 759.3] | Phase 2 | [2] | ||
| Company |
Vertex
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Amiloride-sensitive sodium channel (ENaC) | Target Info | Inhibitor | [3] |
| KEGG Pathway | Taste transduction | |||
| Aldosterone-regulated sodium reabsorption | ||||
| Pathwhiz Pathway | Kidney Function | |||
| Reactome | Stimuli-sensing channels | |||
| WikiPathways | Nuclear Receptors Meta-Pathway | |||
| Iron uptake and transport | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02709109) A Study to Evaluate the Safety and Efficacy of VX-371 in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation. U.S. National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT02871778) Clearing Lungs With ENaC Inhibition in Primary Ciliary Dyskinesia (CLEAN-PCD). U.S. National Institutes of Health. | |||
| REF 3 | The in vitro effect of nebulised hypertonic saline on human bronchial epithelium. Eur Respir J. 2018 May 17;51(5):1702652. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.